Related Experiment Video
Updated: Mar 16, 2026
05:32
A Detailed Protocol for Perspiration Monitoring Using a Novel, Small, Wireless Device
Published on: November 24, 2016
8.3K
Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis
M Bergón-Sendín1, A Pulido-Pérez1, L C Sáez-Martín1
1Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Actas Dermo-Sifiliograficas
|August 8, 2016
Summary
Transdermal oxybutynin patches show promise for treating hyperhidrosis, with significant improvements in symptoms and a favorable safety profile. This new formulation offers a potentially well-tolerated alternative for managing excessive sweating.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Hyperhidrosis significantly impacts patient quality of life.
- Oral oxybutynin is effective but often causes intolerable side effects.
- Transdermal oxybutynin patch is a new formulation for hyperhidrosis treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of transdermal oxybutynin patches.
- To assess treatment response in patients with hyperhidrosis.
Main Methods:
- Prospective study of 25 hyperhidrosis patients.
- Treatment with transdermal oxybutynin patches twice weekly for 10 weeks.
- Assessment using Hyperhidrosis Disease Severity Scale (HDSS) and visual analog scale (VAS).
Main Results:
- 60% of patients showed improvement in HDSS scores.
- All patients experienced improvement in VAS scores for sweating.
- Only 8% of patients reported mild, localized adverse effects (irritant dermatitis).
Conclusions:
- Transdermal oxybutynin demonstrates potential as an effective hyperhidrosis treatment.
- The patch formulation exhibits an excellent safety and tolerability profile.
- Further studies are warranted due to the small sample size.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
97
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
97
01:22Drug Delivery: Miscellaneous Routes
945
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
945
01:24Cholinergic Antagonists: Pharmacokinetics
1.1K
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.1K